An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of 20 mg/kg Oral Deferasirox in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals Corporation
Most Recent Events
- 06 Sep 2014 New trial record